Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06177964 · ClinicalTrials.gov registry record · Phase 2
Lerapolturev (PVSRIPO) in GBM
A Phase 2 study of Recurrent Supratentorial Glioblastoma, sponsored by Darell Bigner.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT06177964 is a Phase 2 study of Recurrent Supratentorial Glioblastoma that is actively recruiting participants, run by Darell Bigner. The registered enrollment target is 92 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06177964, a Phase 2 study of Recurrent Supratentorial Glioblastoma, is actively recruiting participants, sponsored by Darell Bigner.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
Conditions Studied
Interventions
- DRUG Lerapolturev
- DRUG Lomustine Pill
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06177964
The ClinicalTrials.gov registry entry for NCT06177964 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Darell Bigner, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Supratentorial Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Lerapolturev is the first listed.
NCT06177964 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06177964 about?
NCT06177964 is a clinical study titled "Lerapolturev (PVSRIPO) in GBM". The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of th...
What is the current status of trial NCT06177964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2024-07-15. Estimated completion is 2029-02.
What conditions does trial NCT06177964 study?
This clinical trial studies the following conditions: Recurrent Supratentorial Glioblastoma.
What interventions are being tested in trial NCT06177964?
The interventions under investigation include: Lerapolturev (DRUG), Lomustine Pill (DRUG).
Who is sponsoring clinical trial NCT06177964?
This trial is sponsored by Darell Bigner, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06177964 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Supratentorial Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.